• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌胚纤连蛋白异构体在正常、增生及肿瘤性人类乳腺组织中的分布。

Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues.

作者信息

Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L

机构信息

Department of Clinical Pathomorphology, Academy of Medicine, Poznan, Poland.

出版信息

Int J Cancer. 1994 Oct 1;59(1):11-6. doi: 10.1002/ijc.2910590104.

DOI:10.1002/ijc.2910590104
PMID:7927891
Abstract

Two different oncofetal fibronectins (FN) have been reported: one, generated by O-glycosylation in the splicing region IIICS that is recognized by monoclonal antibody (MAb) FDC-6, and another, recognized by MAb BC-I, generated by the alternative splicing of the FN pre-mRNA which includes an extra type-III repeat called ED-B. Using these and 2 other MAbs (IST-4 which recognizes all different FN isoforms and IST-6 which recognizes only the FN molecules that do not include the ED-B sequence) we have immunohistochemically studied 171 normal, hyperplastic and neoplastic breast-tissue specimens. Although all normal specimens reacted strongly with MAbs IST-4 and IST-6, they did not show the presence of oncofetal FNs as established by the use of BC-I and FDC-6. In contrast, out of the 97 cases of invasive ductal carcinomas studied, 90 (93%) and 96 (99%) reacted positively with BC-I and FDC-6, respectively, the reaction being observed in the tumoral stroma connective tissue and in tumoral vessels. Furthermore, invasive lobular carcinoma showed less intense and less frequent staining with BC-1 and FDC-6 (10 and 11 out of 14, respectively). We found differences in the distribution of the 2 oncofetal fibronectin isoforms within the same specimens. The most remarkable difference was observed in the tumoral vessels: in invasive ductal carcinoma MAb BC-1 revealed a positive reaction with vessels in 78% of cases while FDC-6 showed such a reaction in only 59% of cases.

摘要

已有报道称存在两种不同的癌胚纤连蛋白(FN):一种是在剪接区域IIICS通过O-糖基化产生的,可被单克隆抗体(MAb)FDC-6识别;另一种是由FN前体mRNA的可变剪接产生的,可被MAb BC-1识别,该可变剪接包含一个额外的III型重复序列,称为ED-B。使用这些以及另外两种单克隆抗体(识别所有不同FN异构体的IST-4和仅识别不包含ED-B序列的FN分子的IST-6),我们对171例正常、增生性和肿瘤性乳腺组织标本进行了免疫组织化学研究。尽管所有正常标本与单克隆抗体IST-4和IST-6反应强烈,但使用BC-1和FDC-6检测时,它们并未显示癌胚FN的存在。相比之下,在研究的97例浸润性导管癌病例中,分别有90例(93%)和96例(99%)与BC-1和FDC-6呈阳性反应,在肿瘤间质结缔组织和肿瘤血管中均观察到该反应。此外,浸润性小叶癌与BC-1和FDC-6的染色强度较低且频率较低(分别为14例中的10例和11例)。我们发现在同一标本中两种癌胚纤连蛋白异构体的分布存在差异。最显著的差异出现在肿瘤血管中:在浸润性导管癌中,MAb BC-1在78%的病例中显示血管呈阳性反应,而FDC-6仅在59%的病例中显示该反应。

相似文献

1
Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues.癌胚纤连蛋白异构体在正常、增生及肿瘤性人类乳腺组织中的分布。
Int J Cancer. 1994 Oct 1;59(1):11-6. doi: 10.1002/ijc.2910590104.
2
Immunohistochemical fibronectin staining pattern and prognosis in invasive breast carcinoma.
Oncology. 1995 Mar-Apr;52(2):106-11. doi: 10.1159/000227439.
3
Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast.正常、增生及肿瘤性乳腺中的细胞外基质蛋白及其受体
Cell Differ Dev. 1990 Dec 2;32(3):409-16. doi: 10.1016/0922-3371(90)90057-4.
4
Oncofetal fibronectins in oral carcinomas: correlation of two different types.口腔癌中的癌胚纤连蛋白:两种不同类型的相关性
APMIS. 1994 Sep;102(9):695-702.
5
Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.乳腺原位癌、浸润性癌和转移性癌中的血管基质形成。
Clin Cancer Res. 1999 May;5(5):1041-56.
6
The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis.含有ED-B癌胚结构域的纤连蛋白异构体:血管生成的标志物。
Int J Cancer. 1994 Dec 1;59(5):612-8. doi: 10.1002/ijc.2910590507.
7
The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma.由单克隆抗体FDC-6定义的纤连蛋白的癌胚结构域:其在胎儿和肿瘤组织来源的纤连蛋白中存在,而在正常成人组织和血浆来源的纤连蛋白中不存在。
Proc Natl Acad Sci U S A. 1985 Oct;82(19):6517-21. doi: 10.1073/pnas.82.19.6517.
8
Expression of fibronectin isoforms in human breast tissue: production of extra domain A+/extra domain B+ by cancer cells and extra domain A+ by stromal cells.纤连蛋白亚型在人乳腺组织中的表达:癌细胞产生额外结构域A+/额外结构域B+,基质细胞产生额外结构域A+。
Jpn J Cancer Res. 1999 Mar;90(3):320-5. doi: 10.1111/j.1349-7006.1999.tb00750.x.
9
Distribution of oncofetal fibronectin in human mammary tumors: immunofluorescence study on histological sections.癌胚纤连蛋白在人乳腺肿瘤中的分布:组织切片的免疫荧光研究
Cancer Res. 1990 Mar 1;50(5):1608-12.
10
Distribution of fibronectin isoforms in human renal disease.纤连蛋白异构体在人类肾脏疾病中的分布。
J Pathol. 2001 Feb;193(2):256-62. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH783>3.0.CO;2-P.

引用本文的文献

1
Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin.用基于 TCR 的嵌合抗原受体靶向含有额外结构域 B 的纤维连接蛋白治疗实体瘤。
J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2023-007199.
2
RNA-Seq Analysis of Extradomain A and Extradomain B Fibronectin as Extracellular Matrix Markers for Cancer.RNA-Seq 分析细胞外结构域 A 和细胞外结构域 B 纤连蛋白作为癌症细胞外基质标志物。
Cells. 2023 Feb 21;12(5):685. doi: 10.3390/cells12050685.
3
PET Imaging of Hepatocellular Carcinoma Using ZD2-(Ga-NOTA).
使用ZD2-(Ga-NOTA)对肝细胞癌进行正电子发射断层显像(PET)成像。
J Hepatocell Carcinoma. 2023 Feb 22;10:291-301. doi: 10.2147/JHC.S390939. eCollection 2023.
4
The Blessed Union of Glycobiology and Immunology: A Marriage That Worked.糖生物学与免疫学的美满结合:一场成功的联姻
Medicines (Basel). 2023 Jan 19;10(2):15. doi: 10.3390/medicines10020015.
5
FN1 encoding fibronectin as a pivotal signaling gene for therapeutic intervention against pancreatic cancer.FN1 编码纤连蛋白作为治疗胰腺癌的关键信号基因。
Mol Genet Genomics. 2022 Nov;297(6):1565-1580. doi: 10.1007/s00438-022-01943-w. Epub 2022 Aug 18.
6
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade.抗纤连蛋白外显子 B 剪接变异体抗体药物偶联物与免疫检查点阻断联合使用时,可增强疗效,消除肿瘤。
Mol Cancer Ther. 2022 Sep 6;21(9):1462-1472. doi: 10.1158/1535-7163.MCT-22-0099.
7
EDB Fibronectin-Specific SPECT Probe Tc-HYNIC-ZD2 for Breast Cancer Detection.用于乳腺癌检测的EDB纤连蛋白特异性SPECT探针Tc-HYNIC-ZD2
ACS Omega. 2017 Jun 30;2(6):2459-2468. doi: 10.1021/acsomega.7b00226. Epub 2017 Jun 2.
8
Magnetic resonance molecular imaging of metastatic breast cancer by targeting extradomain-B fibronectin in the tumor microenvironment.通过靶向肿瘤微环境中的外显结构域 B 型纤连蛋白对转移性乳腺癌进行磁共振分子成像。
Magn Reson Med. 2018 Jun;79(6):3135-3143. doi: 10.1002/mrm.26976. Epub 2017 Oct 29.
9
ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology.ED-B纤连蛋白表达是转化肿瘤学中上皮-间质转化的一个标志物。
Oncotarget. 2017 Jan 17;8(3):4914-4921. doi: 10.18632/oncotarget.13615.
10
Fibronectin Mechanobiology Regulates Tumorigenesis.纤连蛋白力学生物学调控肿瘤发生。
Cell Mol Bioeng. 2016;9:1-11. doi: 10.1007/s12195-015-0417-4. Epub 2015 Aug 15.